|
1.
|
|
10 p, 1.3 MB |
Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral-induced sustained virologic response
/
Franco Cirera, Sandra (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Llibre, Josep M.. (Institut Germans Trias i Pujol) ;
Jou, Toni (Fundació LLuita Contra les Infeccions) ;
Tural, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez, Miguel Angel (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Universitat Autònoma de Barcelona
In a previous recent work, we recognized three plasma circulating microRNAs (miRNAs)-miR-100-5p_iso3p:-2, miR-122-5p, and miR-192-5p-that correlate largely with liver fibrosis evolution in human immunodeficiency virus type 1 (HIV-1)/hepatitis C virus (HCV) co-infected patients. [...]
2023 -  10.1016/j.heliyon.2022.e12686
Heliyon, Vol. 9 (january 2023)
|
|
|
2.
|
|
2.6 MB |
Nuevos horizontes en la epidemiología, clínica, tratamiento y cribado de la infección por el virus de la hepatitis C en la era de los antivirales de acción directa
/
Llaneras Artigues, Jordi ;
Buti, Maria, dir. ;
Riveiro Barciela, Mar, dir.
La infecció pel virus de l'hepatitis C ha canviat radicalment després de l'aparició dels nous antivirals d'acció directa, fet que ha permès plantejar-se fins i tot l'eradicació de la infecció. [...]
La infección por el virus de la hepatitis C ha cambiado radicalmente tras la aparición de los nuevos antivirales de acción directa, hecho que ha permitido hasta plantearse la erradicación de la infección. [...]
Hepatitis C virus infection has undergone a radical change in recent years. The emergence of new direct-acting antivirals has made possible to consider strategies for eradicating the infection. The aim of this thesis is to establish new horizons towards the identification, screening, and management of hepatitis C from three different angles such as epidemiology, treatment, and screening. [...]
2022
|
|
|
3.
|
|
14 p, 2.9 MB |
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
/
Brochado Kith, Óscar (Instituto de Salud Carlos III) ;
Martínez, Isidoro (Instituto de Salud Carlos III) ;
Berenguer, Juan (Hospital General Universitario Gregorio Marañón) ;
Medrano, Luz María (Instituto de Salud Carlos III) ;
González-García, Juan (Hospital Universitario La Paz (Madrid)) ;
Jiménez-Sousa, María Ángeles (Instituto de Salud Carlos III) ;
Carrero, Ana (Hospital General Universitario Gregorio Marañón) ;
Hontañón Antoñana, Víctor (Hospital Universitario La Paz (Madrid)) ;
Navarro, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Guardiola Tey, Jose Maria (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández-Rodríguez, Amanda (Instituto de Salud Carlos III) ;
Resino, Salvador (Instituto de Salud Carlos III) ;
Miralles, P. (GESIDA Study Group) ;
López, J.C. (GESIDA Study Group) ;
Parras, F. (GESIDA Study Group) ;
Padilla, B. (GESIDA Study Group) ;
Aldámiz-Echevarría, T (GESIDA Study Group) ;
Tejerina, F. (GESIDA Study Group) ;
Díez, C. (GESIDA Study Group) ;
Pérez-Latorre, L. (GESIDA Study Group) ;
Fanciulli, C. (GESIDA Study Group) ;
Gutiérrez, I. (GESIDA Study Group) ;
Ramírez, M. (GESIDA Study Group) ;
Carretero, S. (GESIDA Study Group) ;
Bellón, José-María (GESIDA Study Group) ;
Bermejo, Javier (GESIDA Study Group) ;
Arribas, Jose (GESIDA Study Group) ;
Montes, M.L. (GESIDA Study Group) ;
Bernardino, I. (GESIDA Study Group) ;
Pascual, J.F. (GESIDA Study Group) ;
Zamora, Francisco (GESIDA Study Group) ;
Peña, J.M. (GESIDA Study Group) ;
Arnalich, F. (GESIDA Study Group) ;
Díaz, M. (GESIDA Study Group) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Van den Eynde, E. (Hospital Universitari Vall d'Hebron) ;
Pérez, M. (GESIDA Study Group) ;
Ribera, E. (Hospital Universitari Vall d'Hebron) ;
Crespo Casal, Manuel (Hospital Universitari Vall d'Hebron) ;
Casado, José Luis (GESIDA Study Group) ;
Dronda, F. (GESIDA Study Group) ;
Moreno, A. (GESIDA Study Group) ;
Pérez-Elías, M.J. (GESIDA Study Group) ;
Sanfrutos, M.A. (GESIDA Study Group) ;
Moreno, S. (GESIDA Study Group) ;
Quereda, C. (GESIDA Study Group) ;
Arranz, A. (GESIDA Study Group) ;
Casas, E. (GESIDA Study Group) ;
de Miguel, J. (GESIDA Study Group) ;
Schroeder, S. (GESIDA Study Group) ;
Sanz, J. (GESIDA Study Group) ;
Santos, I. (GESIDA Study Group) ;
Bustinduy, M.J. (GESIDA Study Group) ;
Iribarren, J.A. (GESIDA Study Group) ;
Rodríguez-Arrondo, F. (GESIDA Study Group) ;
Von-Wichmann, M.A. (GESIDA Study Group) ;
Vergas, J. (GESIDA Study Group) ;
Téllez, M.J. (GESIDA Study Group) ;
Vinuesa, D. (GESIDA Study Group) ;
Muñoz, L. (GESIDA Study Group) ;
Hernández-Quero, J. (GESIDA Study Group) ;
Ferrer, A. (GESIDA Study Group) ;
Galindo, María José (GESIDA Study Group) ;
Ortiz, L. (GESIDA Study Group) ;
Ortega, E. (GESIDA Study Group) ;
Montero, M. (GESIDA Study Group) ;
Blanes, M. (GESIDA Study Group) ;
Cuellar, S. (GESIDA Study Group) ;
Lacruz, J. (GESIDA Study Group) ;
Salavert, M. (GESIDA Study Group) ;
López-Aldeguer, J. (GESIDA Study Group) ;
Pérez, G. (GESIDA Study Group) ;
Gaspar, G. (GESIDA Study Group) ;
Yllescas, M. (GESIDA Study Group) ;
Crespo, P. (GESIDA Study Group) ;
Aznar, E. (GESIDA Study Group) ;
Esteban, H. (GESIDA Study Group)
Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). [...]
2021 - 10.1186/s12929-021-00718-6
Journal of Biomedical Science, Vol. 28 Núm. 1 (december 2021) , p. 23
|
|
|
4.
|
|
123 p, 7.3 MB |
Determinación del papel de los microRNAs en el desarrollo de daño hepático en pacientes infectados con el virus de la inmunodeficiencia humana tipo 1
/
Buccione, Daniela ;
Tural i Llacher, C., dir. ;
Martínez de la Sierra, Miguel Angel, dir. ;
Tor Aguilera, Jordi, dir.
Actualment hi ha múltiples marcadors no invasius útils en la predicció de fibrosi hepàtica. Amb la infecció pel VIH-1 la presència de dany hepàtic es veu agreujada per la coinfecció per VHC, el consum d'alcohol i la pròpia teràpia antiretroviral. [...]
Nuestros resultados revelan que la monoinfección por VIH-1 está asociada con una modificación del metabolismo hepático de los miRNAs circulantes, habiéndose detectado una sobre expresión de miRNAs asociados previamente a daño hepático. [...]
Multiple non-invasive markers of liver fibrosis have shown their utility in predicting liver disease. In HIV-1 infected patients, the presence of liver damage is aggravated by HCV coinfection, alcohol abuse, and antiretroviral therapy. [...]
2022
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
14 p, 3.2 MB |
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 + T Cells and Evolve at the Population Level
/
Karimzadeh, Hadi (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ;
Kiraithe, Muthamia M. (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Oberhardt, Valerie (Faculty of Biology, University of Freiburg, Freiburg, Germany) ;
Salimi Alizei, Elahe (Faculty of Chemistry and Pharmacy, University of Freiburg, Freiburg, Germany) ;
Bockmann, Jan (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Schulze zur Wiesch, Julian (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Budeus, Bettina (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ;
Hoffmann, Daniel (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ;
Wedemeyer, Heiner (University Hospital Essen (Alemanya)) ;
Cornberg, Markus (Hannover Medical School. Department of Gastroenterology, Hepatology and Endocrinology) ;
Krawczyk, Adalbert (Department of Infectious Diseases, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany) ;
Rashidi-Alavijeh, Jassin (University Hospital Essen (Alemanya)) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ;
Casillas, Rosario (Hospital Universitari Vall d'Hebron) ;
Buti, Maria (Hospital Universitari Vall d'Hebron) ;
Smedile, Antonina (Department of Medical Sciences, University of Turin, Turin, Italy) ;
Alavian, Seyed Moayed (Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran) ;
Heinold, Andreas (University Hospital Essen (Alemanya)) ;
Emmerich, Florian (Institute for Transfusion Medicine and Gene Therapy, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Panning, Marcus (Institute of Virology, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Gostick, Emma (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ;
Price, David A. (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ;
Timm, Jörg (Institute of Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany) ;
Hofmann, Maike (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Raziorrouh, Bijan (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ;
Thimme, Robert (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Protzer, Ulrike (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Roggendorf, Michael (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Neumann-Haefelin, Christoph (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Universitat Autònoma de Barcelona
Hepatitis D virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progression to liver cirrhosis and hepatocellular carcinoma. Treatment options are limited, and no vaccine is available. [...]
2019 - 10.1053/j.gastro.2019.02.003
Gastroenterology, Vol. 156 (may 2019) , p. 1820-1833
|
|
|
9.
|
|
11 p, 319.6 KB |
Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder
/
Roncero, Carlos (Psychiatric Service, University of Salamanca Health Care Complex, Institute of Biomedicine of Salamanca, University of Salamanca) ;
Ryan, Pablo (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Littlewood, Richard (applied strategic) ;
Macías, Juan (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Ruiz, Juan (Provincial Center of Drug Addiction) ;
Seijo, Pedro (Addiction Treatment Center of Villamartín) ;
Palma-Álvarez, Raúl Felipe (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Vega, Pablo (Institute of Addictions)
People with a history of injecting drugs have high prevalence of hepatitis C virus (HCV) infection, and many have opioid use disorder (OUD). Modern HCV therapies with improved efficacy and tolerability are available, but access is often limited for this group, who may be underserved for health care and face social inequity. [...]
2018 - 10.2147/HMER.S187133
Hepatic Medicine : Evidence and Research, Vol. 11 (december 2018) , p. 1-11
|
|
|
10.
|
|
9 p, 1.3 MB |
Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
/
von Massow, Georg (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia-Cehic, D. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Gregori i Font, Josep (Roche Diagnostics S.L) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Macià, María Dolores (Institut d'Investigació Sanitària Illes Balears) ;
Escarda, Ana (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Esteban Mur, Juan Ignacio (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Quer, Josep 1963- (Universitat Autònoma de Barcelona. Departament de Medicina)
Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. [...]
2019 - 10.2147/IDR.S195441
Infection and drug resistance, Vol. 12 (2019) , p. 947-955
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
